Tyra Biosciences, Inc.
About Tyra Biosciences, Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$119.9M
- Total assets
- $282.6M
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $132.8M
- Operating income
- -$132.8M
- Income tax
- $0
- Net income
- -$119.9M
- EPS (basic)
- $-2.01
- EPS (diluted)
- $-2.01
Balance sheet
- Total assets
- $282.6M
- Current assets
- $265.4M
- Total liabilities
- $23.4M
- Current liabilities
- $18.1M
- Shareholders’ equity
- $259.2M
Cash flow
- Operating cash flow
- -$95.1M
- Investing cash flow
- $72.5M
- Financing cash flow
- $8.1M
- Net cash flow
- -$14.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-2.01
- Shares outstanding
- 59.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $119.9M.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tyra Biosciences, Inc..
Write a review
News about Tyra Biosciences, Inc.
News & sentiment via Polygon.io
